A Prospective, Observational study of the Real World Safety and Effectiveness of the Ultimaster Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions in All-comer Patients (MASTER trial)

Not Applicable

• Conditions: Diseases of the circulatory system

• Registration Number: KCT0006215
• Lead Sponsor: Yonsei University Health System, Yongin Severance Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 June 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

(1) 19 years of age or older
(2) Clinical evidence of coronary artery disease, including asymptomatic ischemia, stable angina, and acute coronary syndrome (unstable angina, non-ST segmented elevated myocardial infarction, ST segmented elevated myocardial infarction)
(3) Unlimited vessel numbers, lesion variables, and lesion length
(4) A person who voluntarily agrees to participate in this clinical study;

Exclusion Criteria

(1) Life expectancy within one year
(2) Persons with known intolerance of the following drugs or substances: heparin, aspirin, clopidogrel, prasugrel, ticagrelor;
(3) If other researchers find it inappropriate to participate in this research,

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence of targeted lesion failures (combination of cardiac death, targeted vascular myocardial infarction, targeted lesion revascularization)

Secondary Outcome Measures

Name	Time	Method
One-year major cardiac problems (all cause of death, myocardial infarction, stent thrombosis, target lesion revascularization).;Incidence rate of cardiac death in one year;Incidence of non-cardiac deaths in a year.;Incidence of target vessel myocardial infarction in a year.;Incidence of non-target vessel myocardial infarction in a year.;One-year ischemic-induced target lesion revascularization;One-year non-ischemic-inducing target lesion revascularization;Incidence of acute stent thrombosis within 24 hours, subacute stent thrombosis within 30 days, and late stent thrombosis for one year;a one-year stroke;Annual Bleeding Rate;Reassess primary/secondary efficacy of antiplatelet drugs